Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

renal function
nephropathy
  • 47 views
  • 04 Oct, 2022
  • 119 locations
Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

ras inhibitor
sglt2
atrasentan
total protein
immunosuppressants
  • 31 views
  • 04 Oct, 2022
  • 36 locations
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously

  • 1 views
  • 11 Aug, 2021
  • 1 location
Dapagliflozin in Non-diabetic Stage IV CKD

), including angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), more effectively than non-RAS inhibitor therapy reduce proteinuria, slow progression to ESRD, and even

hemoglobin a1c
diabetes
  • 0 views
  • 08 Dec, 2021
  • 1 location
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose …

solid tumor
  • 36 views
  • 22 Mar, 2022
  • 6 locations